Symbols / SRNE
SRNE Chart
About
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.21M |
| Enterprise Value | 136.30M | Income | -548.00M | Sales | 64.27M |
| Book/sh | -0.38 | Cash/sh | 0.15 | Dividend Yield | — |
| Payout | 0.00% | Employees | 949 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.04 | P/B | -0.01 | P/C | — |
| EV/EBITDA | -0.40 | EV/Sales | 2.12 | Quick Ratio | 0.34 |
| Current Ratio | 0.41 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.69 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 31.10% | Earnings | 2023-05-15 15:00 | ROA | -40.81% |
| ROE | — | ROIC | — | Gross Margin | -245.01% |
| Oper. Margin | -5.11% | Profit Margin | 0.00% | Shs Outstand | 551.28M |
| Shs Float | 539.11M | Short Float | 11.96% | Short Ratio | 4.96 |
| Short Interest | — | 52W High | 0.10 | 52W Low | 0.00 |
| Beta | 1.57 | Avg Volume | 283.21K | Volume | 501.68K |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 23.08% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-1.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
- Sorrento Therapeutics Stock: From Nasdaq Delisting To Penny-Stock Limbo - AD HOC NEWS Sun, 04 Jan 2026 08
- Scilex Holding announces 1-for-35 reverse stock split - Investing.com ue, 15 Apr 2025 07
- Sorrento (SRNE) Stock Is up 140% in Two Days. How Much Higher Can It Go? - Nasdaq Mon, 18 May 2020 07
- Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today? - InvestorPlace Mon, 13 Feb 2023 08
- Where Will Sorrento Therapeutics Be in 1 Year? - The Motley Fool Fri, 22 Jan 2021 08
- Sorrento Therapeutics: From High?Risk Biotech Darling To Penny?Stock Cautionary Tale - AD HOC NEWS Sat, 03 Jan 2026 08
- A SPAC, Spinoff, And Short Squeeze Walk Into A Bar (NASDAQ:SCLX) - Seeking Alpha ue, 24 Jan 2023 08
- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on For - Yahoo Finance Mon, 31 Oct 2022 07
- Why Sorrento Therapeutics Stock Crashed Today - Nasdaq Wed, 22 Feb 2023 08
- 3 High-Risk, High-Reward Stocks to Add to Your Watch List - The Motley Fool ue, 22 Sep 2020 07
- Scilex Holding ends sales agreement, shares details - Investing.com Mon, 03 Mar 2025 08
- From Sorrento to SRNEQ: Anatomy of a Fallen Biotech High?Flyer - AD HOC NEWS Fri, 13 Feb 2026 08
- Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 - Yahoo Finance hu, 26 Sep 2024 07
- An Update On Sorrento: Hitting Rock Bottom And Finding A Shovel (NASDAQ:SCLX) - Seeking Alpha Wed, 22 Feb 2023 08
- 2 Coronavirus Stocks Robinhood Investors Love. Should You? - The Motley Fool Fri, 07 Aug 2020 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | -754.41K | -4.02M |
| TaxRateForCalcs | 0.00 | 0.07 |
| NormalizedEBITDA | -364.52M | -384.43M |
| TotalUnusualItems | -175.41M | -55.41M |
| TotalUnusualItemsExcludingGoodwill | -175.41M | -55.41M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -572.84M | -428.32M |
| ReconciledDepreciation | 13.24M | 12.46M |
| ReconciledCostOfRevenue | 24.53M | 4.71M |
| EBITDA | -539.93M | -439.84M |
| EBIT | -553.17M | -452.30M |
| NetInterestIncome | -8.57M | -10.22M |
| InterestExpense | 8.57M | 10.22M |
| NormalizedIncome | -398.19M | -376.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -572.84M | -428.32M |
| TotalExpenses | 441.34M | 420.95M |
| TotalOperatingIncomeAsReported | -504.31M | -401.45M |
| DilutedAverageShares | 419.31M | 294.77M |
| BasicAverageShares | 419.31M | 294.77M |
| DilutedEPS | -1.37 | -1.45 |
| BasicEPS | -1.37 | -1.45 |
| DilutedNIAvailtoComStockholders | -572.84M | -428.32M |
| AverageDilutionEarnings | 0.00 | 0.00 |
| NetIncomeCommonStockholders | -572.84M | -428.32M |
| NetIncome | -572.84M | -428.32M |
| MinorityInterests | 4.91M | 813.00K |
| NetIncomeIncludingNoncontrollingInterests | -577.76M | -429.14M |
| NetIncomeContinuousOperations | -577.76M | -429.14M |
| EarningsFromEquityInterestNetOfTax | -18.43M | -126.00K |
| TaxProvision | -2.42M | -33.52M |
| PretaxIncome | -561.75M | -462.53M |
| OtherIncomeExpense | -174.67M | -84.26M |
| OtherNonOperatingIncomeExpenses | 736.00K | -28.84M |
| SpecialIncomeCharges | -98.81M | -40.10M |
| OtherSpecialCharges | 50.02M | 30.90M |
| ImpairmentOfCapitalAssets | 124.19M | 0.00 |
| RestructuringAndMergernAcquisition | -75.40M | 9.20M |
| GainOnSaleOfSecurity | -76.60M | -15.31M |
| NetNonOperatingInterestIncomeExpense | -8.57M | -10.22M |
| InterestExpenseNonOperating | 8.57M | 10.22M |
| OperatingIncome | -378.50M | -368.05M |
| OperatingExpense | 407.89M | 407.92M |
| DepreciationAmortizationDepletionIncomeStatement | 4.33M | 4.14M |
| DepreciationAndAmortizationInIncomeStatement | 4.33M | 4.14M |
| Amortization | 4.33M | 4.14M |
| AmortizationOfIntangiblesIncomeStatement | 4.33M | 4.14M |
| ResearchAndDevelopment | 221.23M | 206.92M |
| SellingGeneralAndAdministration | 182.34M | 196.86M |
| GrossProfit | 29.39M | 39.87M |
| CostOfRevenue | 33.45M | 13.03M |
| TotalRevenue | 62.84M | 52.90M |
| OperatingRevenue | 62.84M | 52.90M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TreasurySharesNumber | 7.57M | 7.57M |
| OrdinarySharesNumber | 515.25M | 314.57M |
| ShareIssued | 522.82M | 322.14M |
| NetDebt | 11.78M | 105.94M |
| TotalDebt | 134.50M | 237.58M |
| TangibleBookValue | -235.78M | -260.48M |
| InvestedCapital | 16.81M | 221.35M |
| WorkingCapital | -231.55M | 33.54M |
| NetTangibleAssets | -235.78M | -260.48M |
| CapitalLeaseObligations | 99.09M | 94.97M |
| CommonStockEquity | -18.61M | 78.75M |
| TotalCapitalization | 525.00K | 189.38M |
| TotalEquityGrossMinorityInterest | -21.67M | 78.13M |
| MinorityInterest | -3.06M | -619.00K |
| StockholdersEquity | -18.61M | 78.75M |
| GainsLossesNotAffectingRetainedEarnings | 1.50M | 1.03M |
| TreasuryStock | 49.46M | 49.46M |
| RetainedEarnings | -1.96B | -1.39B |
| AdditionalPaidInCapital | 1.99B | 1.51B |
| CapitalStock | 52.00K | 32.00K |
| CommonStock | 52.00K | 32.00K |
| TotalLiabilitiesNetMinorityInterest | 494.51M | 616.69M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 166.59M | 477.24M |
| OtherNonCurrentLiabilities | 54.26M | 126.11M |
| DerivativeProductLiabilities | 300.00K | 35.70M |
| NonCurrentDeferredLiabilities | 7.69M | 121.37M |
| NonCurrentDeferredRevenue | 7.10M | 118.94M |
| NonCurrentDeferredTaxesLiabilities | 591.00K | 2.43M |
| LongTermDebtAndCapitalLeaseObligation | 104.34M | 194.06M |
| LongTermCapitalLeaseObligation | 85.21M | 83.43M |
| LongTermDebt | 19.13M | 110.63M |
| CurrentLiabilities | 327.92M | 139.45M |
| OtherCurrentLiabilities | 8.20M | 7.93M |
| CurrentDeferredLiabilities | 652.00K | 1.11M |
| CurrentDeferredRevenue | 652.00K | 1.11M |
| CurrentDebtAndCapitalLeaseObligation | 30.17M | 43.52M |
| CurrentCapitalLeaseObligation | 13.88M | 11.54M |
| CurrentDebt | 16.29M | 31.98M |
| OtherCurrentBorrowings | 16.29M | 31.98M |
| PayablesAndAccruedExpenses | 288.91M | 86.89M |
| CurrentAccruedExpenses | 241.39M | 59.48M |
| Payables | 47.52M | 27.41M |
| AccountsPayable | 47.52M | 27.41M |
| TotalAssets | 472.84M | 694.82M |
| TotalNonCurrentAssets | 376.47M | 521.83M |
| OtherNonCurrentAssets | 3.69M | 4.83M |
| InvestmentsAndAdvances | 17.18M | 51.27M |
| LongTermEquityInvestment | 17.18M | 51.27M |
| GoodwillAndOtherIntangibleAssets | 217.17M | 339.23M |
| OtherIntangibleAssets | 136.90M | 259.70M |
| Goodwill | 80.27M | 79.53M |
| NetPPE | 138.44M | 126.50M |
| AccumulatedDepreciation | -51.42M | -43.49M |
| GrossPPE | 189.85M | 169.99M |
| Leases | 16.16M | 15.53M |
| ConstructionInProgress | 18.23M | 7.88M |
| OtherProperties | 86.46M | 85.17M |
| MachineryFurnitureEquipment | 69.00M | 61.41M |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 96.37M | 172.99M |
| OtherCurrentAssets | 3.14M | 7.48M |
| PrepaidAssets | 8.81M | 11.80M |
| Inventory | 9.98M | 8.11M |
| OtherInventories | -24.00K | 106.00K |
| FinishedGoods | 3.40M | 4.70M |
| RawMaterials | 6.60M | 3.30M |
| Receivables | 24.47M | 18.71M |
| AccountsReceivable | 24.47M | 18.71M |
| CashCashEquivalentsAndShortTermInvestments | 49.98M | 126.88M |
| OtherShortTermInvestments | 26.34M | 90.22M |
| CashAndCashEquivalents | 23.63M | 36.66M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -307.51M | -290.69M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 |
| RepaymentOfDebt | -188.31M | -85.66M |
| IssuanceOfDebt | 96.07M | 49.74M |
| IssuanceOfCapitalStock | 402.33M | 201.82M |
| CapitalExpenditure | -13.66M | -8.87M |
| InterestPaidSupplementalData | 1.17M | 1.06M |
| IncomeTaxPaidSupplementalData | 29.00K | 1.20M |
| EndCashPosition | 23.63M | 36.66M |
| BeginningCashPosition | 36.66M | 56.46M |
| EffectOfExchangeRateChanges | -2.37M | 843.00K |
| ChangesInCash | -10.66M | -20.64M |
| FinancingCashFlow | 311.72M | 181.33M |
| CashFlowFromContinuingFinancingActivities | 311.72M | 181.33M |
| NetOtherFinancingCharges | 426.00K | |
| ProceedsFromStockOptionExercised | 1.20M | 15.42M |
| NetCommonStockIssuance | 402.33M | 201.82M |
| CommonStockPayments | 0.00 | 0.00 |
| CommonStockIssuance | 402.33M | 201.82M |
| NetIssuancePaymentsOfDebt | -92.24M | -35.91M |
| NetShortTermDebtIssuance | 96.07M | 49.74M |
| ShortTermDebtIssuance | 96.07M | 49.74M |
| NetLongTermDebtIssuance | -188.31M | -85.66M |
| LongTermDebtPayments | -188.31M | -85.66M |
| LongTermDebtIssuance | 0.00 | |
| InvestingCashFlow | -28.52M | 79.85M |
| CashFlowFromContinuingInvestingActivities | -28.52M | 79.85M |
| NetInvestmentPurchaseAndSale | 0.00 | 124.77M |
| SaleOfInvestment | 0.00 | 124.77M |
| NetBusinessPurchaseAndSale | -14.86M | -36.05M |
| PurchaseOfBusiness | -14.86M | -36.05M |
| NetPPEPurchaseAndSale | -13.66M | -8.87M |
| PurchaseOfPPE | -13.66M | -8.87M |
| OperatingCashFlow | -293.86M | -281.82M |
| CashFlowFromContinuingOperatingActivities | -293.86M | -281.82M |
| ChangeInWorkingCapital | 69.55M | -2.79M |
| ChangeInOtherWorkingCapital | -113.22M | -4.57M |
| ChangeInPayablesAndAccruedExpense | 191.16M | 16.76M |
| ChangeInAccruedExpense | 181.29M | 20.64M |
| ChangeInPayable | 9.87M | -3.88M |
| ChangeInAccountPayable | 9.87M | -3.88M |
| ChangeInPrepaidAssets | 6.80M | -5.74M |
| ChangeInInventory | -9.51M | -6.28M |
| ChangeInReceivables | -5.68M | -2.96M |
| ChangesInAccountReceivables | -5.68M | -2.96M |
| OtherNonCashItems | -64.12M | 61.25M |
| StockBasedCompensation | 74.85M | 90.19M |
| AssetImpairmentCharge | 124.19M | 0.00 |
| DeferredTax | -1.84M | -35.93M |
| DeferredIncomeTax | -1.84M | -35.93M |
| DepreciationAmortizationDepletion | 13.24M | 12.46M |
| DepreciationAndAmortization | 13.24M | 12.46M |
| Depreciation | 12.46M | |
| OperatingGainsLosses | 68.02M | 22.13M |
| EarningsLossesFromEquityInvestments | 18.43M | 126.00K |
| GainLossOnInvestmentSecurities | 76.60M | 15.31M |
| NetIncomeFromContinuingOperations | -577.76M | -429.14M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SRNE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|